Eledon submits FDA IND for tegoprubart islet cell transplant trial in type 1 diabetes

• Eledon submitted an IND to the FDA for a registrational tegoprubart trial in islet cell transplantation for type 1 diabetes.
• The company reaffirmed plans to start its global Phase 3 LEGACY kidney transplant trial in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eledon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609030700PRIMZONEFULLFEED9820837) on September 03, 2026, and is solely responsible for the information contained therein.